Pharmaceutical Partners for Better Healthcare gets new chairman -- Edward Roberts, E. Merck, Germany elected.
"It's an exciting opportunity to take on the leadership of this group," noted Edward Roberts, "At a time when health care issues are so complex, so vital, and so global, I am firmly committed to continuing the PPBH activities that foster true international partnerships and to communicate our unique, global perspective. A perspective, I might add, that is often missing in national healthcare debates."
Established in 1993, PPBH has already sponsored a comprehensive, international study of health care financing and delivery for 12 different countries in North America, Europe and Asia, that has provoked intensive discussion about the future of health care. Additional multi-country studies are underway on the impact of cost-sharing policies in different healthcare systems and the status of insurance risk adjustment mechanisms. Results for both studies will be available later this year.
PPBH has also co-sponsored various international discussion forums on key healthcare issues. In September 1994, the group co-sponsored a workshop on European health care reforms with the London School of Economics and EU institutions. A publication of the proceedings is expected next month. Last November, PPBH held an international roundtable on patient health learning with 23 leaders in the field in conjunction with the US National Pharmaceutical Council. On May 19-20, 1995, PPBH also held an international conference that attracted over 70 groups representing 35-40 million patients from the US and Europe on the topic of keeping patients -- not costs -- center-stage in the world's health care systems.
PPBH's goal is to improve the quality of health care debates around the world and encourage active participation of all parties involved in health care. Its activities supplement those of existing industry trade groups. In 1993, collective sales for PPBH group exceeded US$120 billion annually with collective R&D budgets of over US$20 billion; current figures not available. Member companies are: Belgium (Solvay), Denmark (Novo Nordisk), France (Rhone-Poulenc, Roussel Uclaf, Sanofi), Germany (Bayer, Boehringer Ingelheim, Boehringer Mannheim, Hoechst, Knoll, E. Merck, Schering), Italy (Menarini, Sigma-Tau), Japan (Chugai, Eisai, Takeda), Netherlands (Akzo Nobel/N.V. Organon), Sweden (Astra, Pharmacia), Switzerland (Ciba, Roche, Sandoz), United Kingdom (Glaxo Wellcome, SmithKline Beecham), United States (Allergan, Amgen, American Home Products, Bristol-Myers Squibb, Johnson & Johnson, Lilly, Marion Merrell Dow, Merck, Pfizer, Procter & Gamble, Schering-Plough, Searle, UpJohn, Warner-Lambert).
Roberts is a Member of the Board of E. Merck, Germany, and responsible for the company's pharmaceutical sector. E. Merck is an international company with worldwide consolidated sales of about DM 6 billion with operations in pharmaceuticals, special and fine chemicals and the laboratory sector. E. Merck, with headquarters in Darmstadt, Germany, employs more than 26,000 people worldwide.
CONTACT: Pharmaceutical Partners for Better Healthcare
Monica Ryser-Cseri, +41-61-261-4709 or 4200
|Printer friendly Cite/link Email Feedback|
|Date:||May 30, 1995|
|Previous Article:||Sallie Mae files lawsuit concerning proxy solicitation.|
|Next Article:||Conseco Shareholders Elect Three Directors, Approve Deferred Compensation Plan.|